Lipocine (NASDAQ:LPCN) Stock Price Crosses Below Two Hundred Day Moving Average – Here’s Why

Lipocine Inc. (NASDAQ:LPCN)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.64 and traded as low as $2.26. Lipocine shares last traded at $2.26, with a volume of 55,639 shares trading hands.

Analyst Upgrades and Downgrades

LPCN has been the subject of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lipocine in a report on Friday, March 27th. Wall Street Zen lowered shares of Lipocine from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Lipocine in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Lipocine presently has an average rating of “Hold” and an average target price of $15.00.

Lipocine Price Performance

The firm has a market capitalization of $18.62 million, a price-to-earnings ratio of -1.20 and a beta of 0.50. The stock has a 50 day moving average price of $4.48 and a two-hundred day moving average price of $5.64.

Lipocine (NASDAQ:LPCN) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.03). The firm had revenue of $0.12 million for the quarter, compared to analysts’ expectations of $0.16 million. Lipocine had a negative net margin of 571.18% and a negative return on equity of 66.70%. As a group, research analysts expect that Lipocine Inc. will post -1.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Lipocine news, Director John W. Higuchi bought 123,000 shares of Lipocine stock in a transaction on Monday, April 6th. The shares were bought at an average cost of $2.05 per share, for a total transaction of $252,150.00. Following the acquisition, the director directly owned 163,797 shares in the company, valued at $335,783.85. This represents a 301.49% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Mahesh V. Patel purchased 25,000 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was acquired at an average cost of $2.03 per share, with a total value of $50,750.00. Following the transaction, the chief executive officer directly owned 160,679 shares in the company, valued at $326,178.37. This trade represents a 18.43% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 213,000 shares of company stock valued at $434,600 in the last 90 days. Company insiders own 6.35% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Citadel Advisors LLC acquired a new position in Lipocine during the 3rd quarter worth $41,000. Jane Street Group LLC purchased a new position in shares of Lipocine in the 4th quarter valued at about $85,000. Dimensional Fund Advisors LP boosted its stake in shares of Lipocine by 57.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 19,122 shares of the specialty pharmaceutical company’s stock valued at $153,000 after buying an additional 6,982 shares during the period. Renaissance Technologies LLC grew its position in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after buying an additional 1,300 shares in the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Lipocine during the fourth quarter worth approximately $441,000. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.